Of those patients receiving 1L ipi-nivo, 44% (12 of 27 tested) were PD-L1 positive (tumor proportion score of ≥1%); whereas for patients with 2L+ ipi-nivo, only 29% (9 out of 31) were PD-L1 positive. This evidence concerns the gene CD274 and neoplasm.